Malaria vaccine development: lessons from the field (Q47911278)

6 February 2018

title

Malaria vaccine development: lessons from the field (English)

1 reference

6 February 2018

0 references

1 reference

2

Philip Bejon

1 reference

6 February 2018

Stephen Todryk

1

1 reference

6 February 2018

language of work or name

English

0 references

publication date

1 August 2009

1 reference

6 February 2018

European Journal of Immunology

published in

1 reference

6 February 2018

volume

39

1 reference

6 February 2018

issue

8

1 reference

6 February 2018

page(s)

2007-2010

1 reference

6 February 2018

Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

The global distribution of clinical episodes of Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Immunity to malaria: more questions than answers

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Failure to respond to the surface of Plasmodium falciparum infected erythrocytes predicts susceptibility to clinical malaria amongst African children

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Plasmodium falciparum variant surface antigen expression patterns during malaria

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Transient cross-reactive immune responses can orchestrate antigenic variation in malaria

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Protection against clinical malaria by heterologous immunoglobulin G antibodies against malaria-infected erythrocyte variant surface antigens requires interaction with asymptomatic infections

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Profiling the antibody immune response against blood stage malaria vaccine candidates

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Anti-sporozoite antibodies and immunity to malaria in a rural Gambian population

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Aspects of genetic susceptibility to human infectious diseases

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Sustainability of reductions in malaria transmission and infant mortality in western Kenya with use of insecticide-treated bednets: 4 to 6 years of follow-up

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Presumptive treatment of fever cases as malaria: help or hindrance for malaria control?

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939529

7 January 2021

Identifiers

DOI

10.1002/EJI.200939529

1 reference

6 February 2018

1 reference

6 February 2018